Search

Your search keyword '"Drinker, Mark S."' showing total 3 results
Start Over Author "Drinker, Mark S." Topic immunity
3 results on '"Drinker, Mark S."'

1. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines

Author

Moody, M Anthony, Liao, Hua-Xin, Alam, S Munir, Scearce, Richard M, Plonk, M Kelly, Kozink, Daniel M, Drinker, Mark S, Zhang, Ruijun, Xia, Shi-Mao, Sutherland, Laura L, Tomaras, Georgia D, Giles, Ian P, Kappes, John C, Ochsenbauer-Jambor, Christina, Edmonds, Tara G, Soares, Melina, Barbero, Gustavo, Forthal, Donald N, Landucci, Gary, Chang, Connie, King, Steven W, Kavlie, Anita, Denny, Thomas N, Hwang, Kwan-Ki, Chen, Pojen P, Thorpe, Philip E, Montefiori, David C, and Haynes, Barton F

Subjects
Infectious Diseases, Clinical Research, Immunization, Biotechnology, HIV/AIDS, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Infection, Antibodies, Antiphospholipid, Antibodies, Monoclonal, CD4-Positive T-Lymphocytes, Cardiolipins, Cell Fusion, Chemokine CCL3, Chemokine CCL4, Chemokines, Chemokines, CC, Complementarity Determining Regions, Culture Media, Conditioned, Endotoxins, Epithelial Cells, Giant Cells, HIV-1, Humans, Immunity, Innate, Immunoglobulin Fab Fragments, Immunoglobulin Fc Fragments, Kinetics, Leukocytes, Mononuclear, Monocytes, Mutation, Phosphatidylethanolamines, Phosphatidylserines, Receptors, CCR5, Viral Tropism, Virus Internalization, beta 2-Glycoprotein I, env Gene Products, Human Immunodeficiency Virus, Medical and Health Sciences, Immunology
Abstract

Traditional antibody-mediated neutralization of HIV-1 infection is thought to result from the binding of antibodies to virions, thus preventing virus entry. However, antibodies that broadly neutralize HIV-1 are rare and are not induced by current vaccines. We report that four human anti-phospholipid monoclonal antibodies (mAbs) (PGN632, P1, IS4, and CL1) inhibit HIV-1 CCR5-tropic (R5) primary isolate infection of peripheral blood mononuclear cells (PBMCs) with 80% inhibitory concentrations of

Published
2010

2. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.

Author

Moody, M Anthony, Liao, Hua-Xin, Alam, S Munir, Scearce, Richard M, Plonk, M Kelly, Kozink, Daniel M, Drinker, Mark S, Zhang, Ruijun, Xia, Shi-Mao, Sutherland, Laura L, Tomaras, Georgia D, Giles, Ian P, Kappes, John C, Ochsenbauer-Jambor, Christina, Edmonds, Tara G, Soares, Melina, Barbero, Gustavo, Forthal, Donald N, Landucci, Gary, Chang, Connie, King, Steven W, Kavlie, Anita, Denny, Thomas N, Hwang, Kwan-Ki, Chen, Pojen P, Thorpe, Philip E, Montefiori, David C, and Haynes, Barton F

Subjects
Leukocytes, Mononuclear, CD4-Positive T-Lymphocytes, Monocytes, Epithelial Cells, Giant Cells, Humans, HIV-1, Phosphatidylethanolamines, Cardiolipins, Phosphatidylserines, Complementarity Determining Regions, Receptors, CCR5, Chemokines, Chemokines, CC, Endotoxins, Antibodies, Monoclonal, Antibodies, Antiphospholipid, Culture Media, Conditioned, Cell Fusion, Kinetics, Mutation, Immunoglobulin Fab Fragments, Immunoglobulin Fc Fragments, beta 2-Glycoprotein I, Virus Internalization, env Gene Products, Human Immunodeficiency Virus, Chemokine CCL3, Chemokine CCL4, Immunity, Innate, Viral Tropism, Leukocytes, Mononuclear, Receptors, CCR5, CC, Antibodies, Monoclonal, Antiphospholipid, Culture Media, Conditioned, env Gene Products, Human Immunodeficiency Virus, Immunity, Innate, Immunology, Medical and Health Sciences
Abstract

Traditional antibody-mediated neutralization of HIV-1 infection is thought to result from the binding of antibodies to virions, thus preventing virus entry. However, antibodies that broadly neutralize HIV-1 are rare and are not induced by current vaccines. We report that four human anti-phospholipid monoclonal antibodies (mAbs) (PGN632, P1, IS4, and CL1) inhibit HIV-1 CCR5-tropic (R5) primary isolate infection of peripheral blood mononuclear cells (PBMCs) with 80% inhibitory concentrations of

Published
2010

3. Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques.

Author

Moody, M. Anthony, Santra, Sampa, Vandergrift, Nathan A., Sutherland, Laura L., Gurley, Thaddeus C., Drinker, Mark S., Allen, Ashley A., Shi-Mao Xia, Meyerhoff, R. Ryan, Parks, Robert, Lloyd, Krissey E., Easterhoff, David, Alam, S. Munir, Hua-Xin Liao, Ward, Brandy M., Ferrari, Guido, Montefiori, David C., Tomaras, Georgia D., Seder, Robert A., and Letvin, Norman L.

Subjects
*TOLL-like receptors, *IMMUNOLOGICAL adjuvants, *CHEMICAL agonists, *CELL-mediated cytotoxicity, *IMMUNITY
Abstract

The development of a vaccine that can induce high titers of functional antibodies against HIV-1 remains a high priority. We have developed an adjuvant based on an oil-in-water emulsion that incorporates Toll-like receptor (TLR) ligands to test whether triggering multiple pathogen-associated molecular pattern receptors could enhance immunogenicity. Compared to single TLR agonists or other pairwise combinations, TLR7/8 and TLR9 agonists combined were able to elicit the highest titers of binding, neutralizing, and antibody-dependent cellular cytotoxicity-mediating antibodies against the protein immunogen, transmitted/ founder HIV-1 envelope gp140 (B.63521). We further found that the combination of TLR7/8 and TLR9 agonists was associated with the release of CXCL10 (IP-10), suggesting that this adjuvant formulation may have optimally stimulated innate and adaptive immunity to elicit high titers of antibodies. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results